Aberrant expression of RANKL and M-CSF by cancer cells has been shown to induce osteoclast activation, leading to bone degradation and the release of growth factors (e.g., IGF-1 and TGF-β) in the bone matrix, stimulating tumor growth [30,31,32]. Here, TGFB1 is linked to neoplasm.